Posluma is a drug owned by Blue Earth Diagnostics Ltd. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 22, 2038. Details of Posluma's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US11413360 | Dual mode radiotracer and—therapeutics |
Nov, 2038
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Posluma's patents.
Latest Legal Activities on Posluma's Patents
Given below is the list of recent legal activities going on the following patents of Posluma.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 10 Jul, 2023 | US11413360 |
| Email Notification | 23 Dec, 2022 | US11413360 |
| Change in Power of Attorney (May Include Associate POA) | 23 Dec, 2022 | US11413360 |
| Correspondence Address Change | 19 Dec, 2022 | US11413360 |
| Patent Issue Date Used in PTA Calculation | 16 Aug, 2022 | US11413360 |
| Recordation of Patent Grant Mailed | 16 Aug, 2022 | US11413360 |
| Email Notification | 28 Jul, 2022 | US11413360 |
| Issue Notification Mailed | 27 Jul, 2022 | US11413360 |
| Mail Response to 312 Amendment (PTO-271) | 06 Jul, 2022 | US11413360 |
| Application Is Considered Ready for Issue | 06 Jul, 2022 | US11413360 |
FDA has granted several exclusivities to Posluma. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Posluma, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Posluma.
Exclusivity Information
Posluma holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Posluma's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
US patents provide insights into the exclusivity only within the United States, but Posluma is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Posluma's family patents as well as insights into ongoing legal events on those patents.
Posluma's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Posluma's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 22, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Posluma Generics:
There are no approved generic versions for Posluma as of now.
About Posluma
Posluma is a drug owned by Blue Earth Diagnostics Ltd. It is used for imaging prostate cancer recurrence. Posluma uses Flotufolastat F-18 Gallium as an active ingredient. Posluma was launched by Blue Earth in 2023.
Market Authorisation Date:
Posluma was approved by FDA for market use on 25 May, 2023.
NCE-1 date:
NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Posluma is 25 May, 2023, its NCE-1 date is estimated to be 26 May, 2027
Active Ingredient:
Posluma uses Flotufolastat F-18 Gallium as the active ingredient. Check out other Drugs and Companies using Flotufolastat F-18 Gallium ingredient
Treatment:
Posluma is used for imaging prostate cancer recurrence.
Dosage:
Posluma is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 25ML (8-158mCi/ML) | SOLUTION | Prescription | INTRAVENOUS |